Vital Signs Reduction Study
Launched by INTERMOUNTAIN HEALTH CARE, INC. · Mar 4, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Vital Signs Reduction Study is looking into how skipping overnight checks of vital signs—like heart rate and temperature—affects the sleep quality and duration of children who are hospitalized. Typically, these checks are done every four hours, but this study aims to find out if they are necessary for all children, especially since they can interrupt sleep. The researchers want to compare the sleep of children who have these checks with those who do not, to see if forgoing them helps kids get better rest during their hospital stay.
To participate in the study, children must be between 1 and 18 years old and hospitalized at Primary Children's Hospital in specific units. They should be stable, meaning their health is not in immediate danger, and a parent or caregiver needs to be available to give permission for them to join the study. Children with certain health conditions or those who have recently had surgery or experienced severe reactions are not eligible. This study is currently recruiting participants, and it offers a chance to contribute to important research that could improve hospital care for kids.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Hospitalized at Primary Children's Hospital on units 3 Southeast, 3 Northeast, 3 Northwest
- • Age 1-18 years
- • Pediatric Early Warning Score ≤ 1 at 2000
- • A parent/home caregiver present to consent to study
- • Patient and home caregiver speak English or Spanish.
- • Deemed appropriate for forgone overnight vital signs by care team (attending MD/Advanced Practice Provider and bedside RN).
- Exclusion Criteria:
- • Pre-existing diagnosis of hypertension, kidney disease, pulmonary hypertension, chronic lung disease, congenital heart disease causing cardiopulmonary compromise, obstructive sleep apnea, seizure disorder, neuromuscular disability.
- • Patients requiring O2 monitoring at home.
- • The following medications in the previous 24 hours: opioids, intravenous immunoglobulin, intravenous magnesium, continuous albuterol, benzodiazepines, other sedating medications beyond home regimen.
- • Anaphylaxis within 24 hours
- • Within the first 24 hours post-operative period
- • Requiring oxygen above baseline
- • Fever in the last 24 hours.
- • Sepsis alert in the last 72 hours.
About Intermountain Health Care, Inc.
Intermountain Health Care, Inc. is a leading nonprofit healthcare system based in Salt Lake City, Utah, dedicated to improving community health through innovative clinical practices and rigorous research initiatives. With a commitment to evidence-based care and patient-centered approaches, Intermountain actively sponsors clinical trials that aim to advance medical knowledge and enhance treatment options across various health conditions. The organization leverages its extensive network of hospitals, outpatient facilities, and specialized care services to facilitate high-quality research while prioritizing patient safety and ethical standards. Through collaboration with healthcare professionals and academic institutions, Intermountain Health Care strives to contribute significantly to the advancement of healthcare practices and outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Salt Lake City, Utah, United States
Patients applied
Trial Officials
Leandra Bitterfeld, MSN
Principal Investigator
Intermountain Primary Children's Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported